Pilot Study of Continuing Aspirin Versus Switching to Clopidogrel After Stroke or Transient Ischemic Attack

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
University of California, San Diego
ClinicalTrials.gov Identifier:
NCT00363753
First received: August 10, 2006
Last updated: March 30, 2007
Last verified: March 2007
  Purpose

Pilot study of continuing aspirin versus switching to clopidogrel after stroke or transient ischemic attack.


Condition Intervention Phase
Transient Ischemic Attack
Stroke
Aspirin
Clopidogrel
Drug: aspirin versus clopidogrel
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Pilot Study of Continuing Aspirin Versus Switching to Clopidogrel After Stroke or Transient Ischemic Attack

Resource links provided by NLM:


Further study details as provided by University of California, San Diego:

Primary Outcome Measures:
  • mRS at three months.

Secondary Outcome Measures:
  • Incidence of stroke at three months, bleeding events.

Estimated Enrollment: 20
Study Start Date: August 2006
Estimated Study Completion Date: March 2007
Detailed Description:

Pilot study of continuing aspirin versus switching to clopidogrel after stroke or transient ischemic attack.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18 and older.
  • Stroke or transient ischemic attack (TIA) while taking aspirin within one week of consent.
  • Women of child-bearing potential will be included only if there is a negative pregnancy test and they agree to birth control during the treatment period.

Exclusion Criteria:

  • Any medical indication for a specific antiplatelet agent (aspirin, clopidogrel, ticlopidine, aggrenox), or an indication for a combination of antiplatelet agents.
  • Any medical indication for anticoagulation, except subcutaneous heparin for deep vein thrombosis prophylaxis.
  • Allergy to aspirin or clopidogrel.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00363753

Locations
United States, California
UCSD
San Diego, California, United States, 92103
UCSD Hillcrest
San Diego, California, United States, 92103
Sponsors and Collaborators
University of California, San Diego
Investigators
Principal Investigator: Matt B Jensen, MD UCSD Stroke Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00363753     History of Changes
Other Study ID Numbers: UCSD IRB #060452
Study First Received: August 10, 2006
Last Updated: March 30, 2007
Health Authority: United States: Institutional Review Board

Keywords provided by University of California, San Diego:
Transient ischemic attack
Stroke
Aspirin
Clopidogrel

Additional relevant MeSH terms:
Ischemia
Ischemic Attack, Transient
Brain Ischemia
Cerebral Infarction
Stroke
Brain Diseases
Brain Infarction
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Nervous System Diseases
Pathologic Processes
Vascular Diseases
Aspirin
Clopidogrel
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antipyretics
Antirheumatic Agents
Cardiovascular Agents
Central Nervous System Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents

ClinicalTrials.gov processed this record on October 22, 2014